Glaucoma Medication Groups | Medicine | Formulation and strength | Availability n (%) | Target Size Pack |
Alpha-Adrenergic Receptor Agonists | Apraclonidine | Eye drop, 0.5% | 0 (0.0%) | 5 mL |
Brimonidine | Eye drop, 0.2% | 4 (10.3%) | 5 mL | |
Beta-Blockers | Timolol | Eye drop, 0.5% | 28 (71.8%) | 5 mL |
Carteolol | Eye drop, 1% | 0 (0.0%) | 5 mL | |
Levobunolol | Eye drop, 0.5% | 0 (0.0%) | 5 mL | |
Betaxolol | Eye drop, 0.5% | 3 (7.7%) | 5 mL | |
Cholinergic Agonists | Pilocarpine | Eye drop, 1% | 2 (5.1%) | 10 mL |
Carbachol | Eye drop, 3% | 0 (0.0%) | 15 mL | |
Carbonic Anhydrase Inhibitors | Acetazolamide | Tablet, 250 mg | 7 (17.9%) | 30 Tablets |
Brinzolamide | Eye drop, 1% | 0 (0.0%) | 5 mL | |
Dorzolamide | Eye drop, 2% | 5 (12.8%) | 5 mL | |
Prostaglandin Analogues | Bimatoprost | Eye drop, 0.03% | 0 (0.0%) | 3 mL |
Travoprost | Eye drop, 0.004% | 0 (0.0%) | 2.5 mL | |
Unoprostone | Eye drop, 0.15% | 0 (0.0%) | 5 mL | |
Latanoprost | Eye drop, 0.005% | 3 (7.7%) | 2.5 mL | |
Mean availability of glaucoma medicines in percentage | 8.89 | |||
Availability category Level n (%) | Very low | Low | Fairly high | High |
<30% | 30 - <50% | 50 - <80% | ≥80% | |
14 (93.3) | 0 (0.0) | 1 (6.67) | 0 (0.0) |